HER3 overexpression and survival in solid tumors: a meta-analysis

Area of Science:

• Oncology
• Molecular Biology
• Biomarkers

Background:

• Human epidermal growth factor receptor 3 (HER3) is a key member of the ErbB/HER family, known to dimerize with other receptors like HER2.
• Despite numerous HER3-targeted agents in development, the prognostic significance of HER3 expression in solid tumors remains variable.
• This meta-analysis investigates the association between HER3 expression and patient survival across various solid malignancies.

Purpose of the Study:

• To conduct a meta-analysis evaluating the prognostic impact of HER3 expression on overall survival (OS) in patients with solid tumors.
• To quantify the association between HER3 expression levels and survival outcomes at 3 and 5 years post-diagnosis.
• To explore potential differences in the impact of HER3 on OS in tumors with and without HER2 overexpression.

Main Methods:

• Systematic literature search of PubMed for studies assessing HER3 expression (via immunohistochemistry) and OS in solid tumors.
• Extraction of published data and calculation of odds ratios (ORs) for mortality at 3 and 5 years.
• Meta-analysis using the Mantel-Haenszel random-effect model for pooled analysis of extracted data.

Main Results:

• The analysis encompassed 12 studies across diverse solid tumors including colorectal, gastric, breast, melanoma, ovarian, head and neck, pancreatic, and cervical cancers.
• A median of 42.2% of cancers exhibited HER3 overexpression.
• HER3 expression was significantly associated with worse OS at both 3 years (OR = 2.24) and 5 years (OR = 2.20).

Conclusions:

• Elevated HER3 expression is a significant indicator of poorer survival outcomes in patients with solid tumors.
• The negative prognostic influence of HER3 on overall survival appears more pronounced in tumors that commonly overexpress HER2, such as breast, gastric, and ovarian cancers.